TrialDrugs in R&D2011

Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.

Jacques Medioni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.